Novartis raises mid-term sales guidance, citing strong drug performance and promising pipeline, but analysts express concerns about sustaining growth beyond 2029.
Alistair Brownlee, a two-time Olympic triathlon champion, retires at 36 after an illustrious career, with plans to explore other endurance challenges while staying active in sports.
Novartis raises mid-term sales guidance, citing strong drug performance and promising pipeline, but analysts express concerns about sustaining growth beyond 2029.
Alistair Brownlee, a two-time Olympic triathlon champion, retires at 36 after an illustrious career, with plans to explore other endurance challenges while staying active in sports.